Bristol Myers Squibb (CELG-RI) Non-Current Debt (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has reported Non-Current Debt for 18 consecutive years, with $42.9 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non-Current Debt fell 12.43% year-over-year to $42.9 billion in Q2 2026; TTM through Jun 2026 was $42.9 billion, a 12.43% decrease from a year earlier, with the FY2025 full-year figure at $44.8 billion, down 9.31% from the prior year.
• Non-Current Debt was $42.9 billion for Q2 2026 at Bristol Myers Squibb, down from $44.1 billion in the prior quarter.
• Over five years, Non-Current Debt peaked at $52.4 billion in Q1 2024 and troughed at $37.0 billion in Q3 2023.
• A 5-year average of $44.3 billion and a median of $44.4 billion in 2022 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt retreated 16.57% in 2023 and soared 40.26% in 2024, its largest moves.
• Over 5 years, Non-Current Debt stood at $39.0 billion in 2022, then grew by 1.47% to $39.5 billion in 2023, then advanced by 25.06% to $49.4 billion in 2024, then slipped by 9.31% to $44.8 billion in 2025, then declined by 4.39% to $42.9 billion in 2026.
• The last three Non-Current Debt figures came in at $42.9 billion (Q2 2026), $44.1 billion (Q1 2026), and $44.8 billion (Q4 2025), per Business Quant data.